UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organi ...

Moderna (MRNA) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of a loss of $0.78 per share. This compares to earnings of $3.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 170.51%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.01 per share when it actually produced a loss of $1.39, delivering a surprise of 30.85%.Over the last four quarters, ...

Fourth Quarter & Full Year 2023 Financial Results l 2024 Priorities Stéphane Bancel, CEO 3 5 © 2024 Moderna, Inc. All rights reserved. Sales at low end of framework at $6.1B, excluding the recognition of $0.6B in deferred revenue related to Gavi • Competitor contract prevented us from competing in the EU in 2H • Strong performance in Israel, Switzerland and Taiwan 4Q 2023 Update| Commercial Market 6 2023 GAAP financial summary Cash and investments: $13.3B 7 © 2024 Moderna, Inc. All rights reserved. 2023 Bus ...

Moderna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge as the world continued to emerge from pandemic and relied less on protective shots and treatments.Here's what Moderna reported for the fourth quarter compared with what Wall Street was expecting, based on a survey ...

Investors are always looking for stocks that are poised to beat at earnings season and Moderna, Inc. (MRNA) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Moderna is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicat ...

We expect Moderna (MRNA) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 22, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 30.85%.Factors to NoteDuring the fourth quarter, sales of COVID-19 vaccines are likely to have declined significantly due to lower demand. The Zacks Consensus Estimate for fourth-quarter product sales is pegged at $2.45 billion.Due to the substantial fall in COVID-19 vaccine sales compared with ...

Moderna (MRNA) closed the latest trading day at $85.95, indicating a +0.68% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 0.96%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 1.3%.Prior to today's trading, shares of the biotechnology company had lost 16.44% over the past month. This has lagged the Medical sector's gain of 1.18% and the S&P 500's gain of 3.69% in that time.The investment community will be closely monitoring the perf ...

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain. The road often exceeds a decade, with the approval process varying significantly by drug type. This complexity, coupled with a staggering 90% failure rate in clinical drug development, underscores the precarious nature of biotech investments.Indeed, the bi ...

Moderna (MRNA) closed the latest trading day at $99.30, indicating a -0.73% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. At the same time, the Dow added 0.41%, and the tech-heavy Nasdaq gained 0.95%.The biotechnology company's stock has dropped by 9.21% in the past month, falling short of the Medical sector's gain of 3.2% and the S&P 500's gain of 5.59%.The investment community will be closely monitoring the performance of Moderna ...

Growth stocks are supposed to, well, grow. That's especially the expectation when the overall stock market soars as it did in 2023.However, even the best growth stocks can experience rough patches. Those periods, though, can present excellent buying opportunities for long-term investors. Here's one growth stock down 79% that's a screaming buy right now, according to several Wall Street analysts.Renewed bullish views about this biotech stockIt doesn't seem all that long ago when Moderna (MRNA 1.68%) was flyi ...